^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ceraxa (nanoliposomal ceramide)

    i
    Other names: KN-001, KN 001, KN-01, CNL
    Company:
    Keystone Nano
    Drug class:
    Apoptosis inducer, PP2A activator
    Related drugs:
    6ms
    Ceramide NanoLiposome in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=14, Completed, Keystone Nano, Inc | Unknown status --> Completed | N=24 --> 14 | Trial completion date: Aug 2019 --> Nov 2023 | Trial primary completion date: Aug 2019 --> Aug 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Ceraxa (nanoliposomal ceramide)
    1year
    A phase I study of the ceramide nanoliposome in patients with advanced solid tumors. (PubMed, Cancer Chemother Pharmacol)
    CNL exhibited an encouraging safety profile and pharmacokinetic parameters, with some signals of efficacy including prolonged stable disease in 1 patient with refractory pancreatic cancer. Pre-clinical data indicate potential synergy between CNL and multiple systemic therapies including chemotherapy, targeted therapy, and immunotherapy. Future studies are planned investigating CNL in combination strategies.
    P1 data • Journal • Metastases
    |
    Ceraxa (nanoliposomal ceramide)